NexEos Bio is focused on bringing novel tools and therapies to market that address the unmet needs of patients suffering with eosinophil and cationic protein-mediated diseases including eosinophilic conjunctivitis and eosinophilic esophagitis (EoE). NexEos Bio is advancing programs in Vision Health, Diagnostic Health, and Maternal Health.

​

NexEos’ lead therapeutic NTX-1024 is a topical ophthalmic solution designed to target and inhibit cationic granule proteins in eosinophil-driven ocular disease such as Vernal Keratoconjunctivitis (VKC). It is being developed as a potential first-in class therapy for conditions such as VKC, with future expansion into broader forms of allergic conjunctivitis.

 

NexEos’ lead diagnostic NDX-3324 is a novel, non-invasive imaging agent for the diagnosis, treatment monitoring, and management of EoE, which has the potential to help improve patients’ quality of life, more rapidly diagnose their disease, and thus may help delay disease progression. 

​